Disease Landscape and Forecast Insights

The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune…

Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…

Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…

Antipsychotics are the standard of care for treating schizophrenia, with oral atypical antipsychotics (e.g., olanzapine, risperidone) experiencing preferential use. Because of the heterogeneity of…

The treatment landscape for major depressive disorder (MDD), consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Therapies to treat MDD…

Parkinson’s disease (PD) is the second-most common neurodegenerative disorder that, according to DRG epidemiology, afflicts more than 1.5 million people in the EU5. Although PD treatment has been…

Most patients with chronic obstructive pulmonary disease (COPD) in the five European countries under study receive treatment shortly after diagnosis. The progressive nature of the disease results…

Hyperkalemia, a condition of elevated serum potassium, arises from disturbances to potassium homeostasis within the body. Among key populations, including patients with kidney disorders and/or HF,…

Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…

Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist for renal anemia, physicians, patients, and healthcare systems are concerned over some…

Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…

Recent launches of Celltrion’s Truxima (rituximab) and Sandoz’s Rixathon (rituximab) have expanded the biosimilar sector of the European oncology market. In the United States, only a single…